Home > Insider Trading > Filing (0001209191-23-053351)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1515673	Ultragenyx Pharmaceutical Inc.	RARE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1248093	D Emil Kakkis	C/O Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato CA 94949	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-10-19	47,853	$6.86	647,029	No	4	M	Direct
Common Stock	Disposition	2023-10-19	47,853	$33.52	599,743	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-10-19	47,853	$0.00	47,853	$6.86

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2023-11-01	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,263,985	Indirect	By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200

Footnotes

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $34.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Includes 567 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023.
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date.